Validation Study of RETINA-AI Galaxy™, an Automated Diabetic Retinopathy Screening Device

NCT ID: NCT04774822

Last Updated: 2021-09-16

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 397 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2021-03-25
• Study Completion Date: 2021-08-31

Brief Summary

Diabetes affects approximately 35 million Americans, each of whom needs at least one retinal exam per year. However, majority do not get their eye exam due to multiple prohibitive factors such as cost, transportation, difficulty of taking time off from work, and inconvenience, amongst others. The standard of care in diabetes requires at least an annual eye exam to detect onset of diabetic retinopathy and to treat when indicated. This is important as diabetes is the most common cause of visual impairment and blindness in working age adults in the United States. There are too few trained professionals to diagnose diabetic retinopathy, this prompted the development of RETINA-AI Galaxy an automated software as a medical device which screens for diabetic retinopathy in the primary care setting. This observational study is designed to validate the safety and efficacy of the device.

Detailed Description

This study is a prospective, multicenter, observational study to assess the safety and efficacy of RETINA-AI Galaxy in screening for diabetic retinopathy in the primary care setting. The study design conforms to an Intent to Screen (ITS) paradigm [1]. The Galaxy is a software medical device designed to analyze digital color fundus photographs and rapidly screen for the presence of more than mild diabetic retinopathy or vision-threatening diabetic retinopathy in the primary care setting.

The study will enroll 360 subjects after exclusions. Subjects who meet eligibility criteria will be recruited from three sites staffed by primary care providers. Eligibility will be assessed and informed consent obtained, after which digital color fundus photographs will be taken using U.S. Food and Drug Administration (FDA) cleared non-mydriatic fundus cameras, by an operator using the Galaxy photography manual.

There will be a total of 5 non-mydriatic robotic screening cameras used in the AI system protocol part of the study. There will be a dedicated validation camera used in the Validation Reading Center Protocol part of the study. Primary care clinical staff (e.g. medical assistant) with no prior professional ophthalmic photography experience and only a 4 hour training will operate the RETINA-AI Galaxy device and the screening cameras. The Retina Reading Center - certified professional ophthalmic photographers will operate the validation fundus cameras according the the 4W-D stereo protocol.

Conditions

Diabetic Retinopathy; Diabetic Eye Problems; Diabetic Macular Edema

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: CROSS_SECTIONAL

Study Groups

Sequential Enrollment

Enrollment based on default inclusion criteria listed below

Color Fundus Photography

Intervention Type: PROCEDURE

Stereoscopic Fundus photography

Mydriatics Agent

Intervention Type: DRUG

Eye dilating agent

Optical Coherence Tomography (OCT)

Intervention Type: PROCEDURE

Optical Tomographic imaging of retina

Enrichment Enrollment

Enrollment based periodic statistician-activated inclusion criteria adjustment to attain statistically adequate distribution

Color Fundus Photography

Intervention Type: PROCEDURE

Stereoscopic Fundus photography

Mydriatics Agent

Intervention Type: DRUG

Eye dilating agent

Optical Coherence Tomography (OCT)

Intervention Type: PROCEDURE

Optical Tomographic imaging of retina

Interventions

Color Fundus Photography

Stereoscopic Fundus photography

Intervention Type: PROCEDURE

Mydriatics Agent

Eye dilating agent

Intervention Type: DRUG

Optical Coherence Tomography (OCT)

Optical Tomographic imaging of retina

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

1. Patient age 22 or above

2. Patient with documented diagnosis of diabetes as defined by:

A. Hemoglobin A1c (HbA1c)>= 6.5% based on repeated assessments

B. Fasting Plasma Glucose (FPG) >= 126 mg/dL (7.0 mmol/L) based on repeated assessments

C. Oral Glucose Tolerance test with 2 hr plasma glucose >= 200 mg/dL (11.1mmol/L) using equivalent of 75g anhydrous glucose dose in water.

D. Symptoms of hyperglycemia or hyperglycemic crisis with random plasma glucose >=200mg/dL (11.1 mmol/L)

E. Per World Health Organization (WHO) or American Diabetes Association diabetes criteria

3. Understanding of the Study and willingness and ability to sign informed consent

Exclusion Criteria

1. Persistent vision loss in one or both eyes

2. Diagnosis with macula edema, severe non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, radiation retinopathy, or retinal vein occlusion

3. History of retinal laser treatment or intraocular injections of other eye; or any prior history of retinal surgery.

4. Current enrolled in another interventional study of an investigational device or drug and actively receiving investigational product for DR or DME

5. Subject has a condition that in the principal investigator's opinion would preclude participation in the study (e.g it may confound study results or result in ungradable photographs for clinical reference standard)

6. Subject has contraindication to mydriatic agent (dilating drops) or is unwilling or unable to dilate

7. Subject is contraindicated from fungus photography (e.g. subject is hypersensitivity to light).

• Minimum Eligible Age: 22 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

RETINA-AI Health, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Biopharma Informatic, LLC

Houston, Texas, United States

Clinical Trial Network

Houston, Texas, United States

Biopharma Informatic LLC

Houston, Texas, United States

Countries

United States

Other Identifiers

RETINA-AI-CT1

Identifier Type: -

Identifier Source: org_study_id